The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
 
Joseph Sacco
Honoraria - Immunocore
Consulting or Advisory Role - BMS; Immunocore; Immunocore (Inst); MSD
Research Funding - AstraZeneca (Inst); BMS (Inst); Immunocore (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Justin Moser
Leadership - Arizona Skin Cancer Foundation
Honoraria - Curio Science; Daiichi Sankyo; Horizon CME; TGen
Consulting or Advisory Role - Adagene; Amunix; Boxer Capital; Bristol-Myers Squibb; Genome Insight; Imaging Endpoints; Incyte; IQVIA; Novotech; Oberland Capital; Pfizer; Red Arrow Therapeutics; Thirona Biosciences; Topotecan Episceral Plaque for Treatment of Retinoblastoma; Vilya; Werewolf Therapeutics (Inst)
Speakers' Bureau - Caris Life Sciences; Castle Biosciences; Immunocore
Research Funding - Agenus (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); BioEclipse Therapeutics (Inst); Fate Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); IDEAYA Biosciences (Inst); ImmuneSensor Therapeutics (Inst); Iovance Biotherapeutics (Inst); ISTARI Oncology (Inst); Nektar (Inst); Novocure (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Storm Therapeutics (Inst); Synthorx (Inst); Trishula Therapeutics (Inst); TScan Therapeutics (Inst); University of Arizona (Inst); Werewolf Therapeutics (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - US PCT/US24/27766
 
Allison Betof Warner
Consulting or Advisory Role - Adaptimmune; BluePath Solutions; Bristol-Myers Squibb/Medarex; immatics; IO Biotech; Iovance Biotherapeutics; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Iovance Biotherapeutics (Inst); Lyell Immunopharma (Inst); Obsid (Inst)
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Georgimmune (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Diwakar Davar
Stock and Other Ownership Interests - mBiomics; Zola
Honoraria - ACM Biolabs; Arcus Biosciences; Ascendis Pharma; Castle Biosciences; Clinical Care Options (CCO); Gerson Lehrman Group; GlaxoSmithKline; Immunocore; Medical Learning Group; Merck; Regeneron; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Alexander Shoushtari
Consulting or Advisory Role - Erasca, Inc; Immunocore
Research Funding - Bristol-Myers Squibb (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Mural Oncology (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Richard Carvajal
Consulting or Advisory Role - Castle Biosciences; Delcath Systems; IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Sapna Patel
Honoraria - Cedars Sinai; Clinical Care Options; Clinical Education Alliance (Inst); Emory University; OncLive/MJH Life Sciences; Paradigm; University of Michigan; Vindico Medical Education (Inst)
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; IDEAYA Biosciences; immatics; IO Biotech; MSD; Novartis; Obsidian Therapeutics; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; Melanoma Research Alliance (MRA); Melanoma Research Foundation; MSD; SITC/ACCC; SWOG; TriSalus Life Sciences
 
Anthony Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods; Use of Darovasertib for Neoadjuvant treatment ocular Melanoma
 
Jessica Hassel
Honoraria - Bristol Myers Squibb Foundation; Delcath Systems; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); Immunocore (Inst); MSD (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - Agenus (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); immatics (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Mark Navarro
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Rahul Marpadga
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Giuseppe Gullo
Employment - Replimune
Stock and Other Ownership Interests - Replimune
 
Marlana Orloff
Employment - Pfizer (I)
Honoraria - Immunocore
Consulting or Advisory Role - Delcath Systems; IDEAYA Biosciences; Immunocore; Replimune; TriSalus Life Sciences
Speakers' Bureau - Immunocore
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Regeneron (Inst); TriSalus Life Sciences (Inst)